PROMIS was registered on ClinicalTrials.gov (NCT01292291), and its design has been discussed elsewhere [6]. In brief, this was a multicentre study in which biopsy-naïve men with PSA ≤15 ng/mL underwent prebiopsy 1.5 T mpMRI, followed by a combined biopsy procedure under general anaesthetic. The combined procedure consisted of 5 mm transperineal template mapping (TPM) biopsy followed by standard systematic TRUS-guided biopsy. Each test was performed and reported by clinicians blinded to other results. For this work, only men enrolled at University College London Hospital (UCLH) were considered (n = 235).

Ethical approval for PROMIS was granted by the National Research Ethics Service Committee London (Ref: 11/LO/0185).

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。